The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function

Documenti analoghi

• Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
  di: Bruneau, J M, et al.
  Pubblicazione: (1998)
• The active metabolite of leflunomide, A77-1726, increases proliferation of human synovial fibroblasts in presence of IL-1β
  di: Magne, D, et al.
  Pubblicazione: (2004)
• Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1β stimulated rheumatoid synovial fibroblasts
  di: MIGITA, K, et al.
  Pubblicazione: (2004)
• The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes
  di: Palmer, Gaby, et al.
  Pubblicazione: (2004)
• Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
  di: van Roon, E N, et al.
  Pubblicazione: (2005)